News
908 Devices Enhances MX908 Usability and Adds New Drug Targets
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
908 Devices Reports Third Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook
908 Devices to Participate in Upcoming Investor Conferences
United States Coast Guard Purchases 908 Devices’ Handheld Mass Spec Devices for Chemical Threat Identification
908 Devices to Report Third Quarter 2025 Financial Results on November 10, 2025
United States Marine Corps Purchases 908 Devices’ XplorIR Gas Identification Devices
908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook
908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors
908 Devices to Participate in the Canaccord Genuity 45th Annual Growth Conference
908 Devices to Report Second Quarter 2025 Financial Results on August 5, 2025
908 Devices Launches VipIR, a 3-in-1 Handheld Analyzer for Field-Based Chemical Identification of Unknown Bulk Substances
908 Devices Appoints Christopher D. Brown to its Board of Directors
Metropolitan Washington Council of Governments Adds 908 Devices’ XplorIR to Its Hazardous Materials Response Toolkit
Romanian Customs Authority Adopts 908 Devices’ MX908 for Border Security Operations
908 Devices to Participate in the William Blair 45th Annual Growth Stock Conference
908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook
908 Devices Equips rescEU Disaster Preparedness Reserve with Advanced Chemical Detection
908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation
908 Devices Announces Preliminary First Quarter 2025 Financial Results
908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
908 Devices to Participate in Upcoming Investor Conferences
908 Devices to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters
908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
908 Devices to Participate in Upcoming Investor Conferences
908 Devices to Report Third Quarter 2024 Financial Results on November 12, 2024
908 Devices to Participate in Craig-Hallum Bioprocessing Conference
908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook
908 Devices to Participate in Canaccord Genuity 44th Annual Growth Conference
908 Devices to Report Second Quarter 2024 Financial Results on August 6, 2024
908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors
908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering
908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024
908 Devices Trace Chemical Identification Technology Adopted by European Agencies
908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook
908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform
908 Devices to Participate in Upcoming Investor Conferences
908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
908 Devices Announces MX908 Integration Capabilities
908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook
908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device
908 Devices to Report Third Quarter Financial Results on November 7, 2023
908 Devices Enters Initial Production Phase of US Department of Defense Aerosol and Vapor Chemical Agent Detector Program
908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters
908 Devices to Participate in the Gilmartin Group Emerging Growth Company Showcase
908 Devices Reports Second Quarter 2023 Financial Results and Updates 2023 Revenue Outlook
908 Devices Partners with Tennessee State and Local Agencies in the Fight Against Drug Trafficking Through a New Pilot Program
908 Devices Launches Remote and Continuous Area Monitoring for Aerosol and Vapor Detection
908 Devices to Report Second Quarter Financial Results on August 8, 2023
908 Devices Features its High-Speed, High-Resolution Separations Technology at the 71st ASMS Conference
908 Devices to Participate in the William Blair 43rd Annual Growth Stock Conference
908 Devices Reports First Quarter 2023 Financial Results and Reiterates 2023 Revenue Outlook
908 Devices Launches Data Analysis Visualization Tool for REBEL At-line Cell Culture Media Analyzer
Resilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices’ REBEL At-line Analyzer
908 Devices to Report First Quarter Financial Results on May 9, 2023
908 Devices Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Revenue Outlook
908 Devices to Participate in the Cowen 43rd Annual Healthcare Conference
908 Devices to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
908 Devices Unveils New Glucose and Lactate On-Line Device for Bioprocess Monitoring and Control
MX908 Device Enables Correctional Facility Personnel to Quickly Identify Illegal Drugs in Incoming Mail
908 Devices Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Outlook
908 Devices Records Strong Momentum in Life Sciences Sector
908 Devices Launches Pesticide Identification Capability to Thwart Illegal Marijuana Growing Operations
908 Devices to Participate in Upcoming Investor Conferences
908 Devices to Report Third Quarter 2022 Financial Results on November 14, 2022
908 Devices and CPI Improve mAbs Cell Culture Outcomes Using At-line Media Analysis
908 Devices Reports Second Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook
908 Devices Reports Second Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook
908 Devices Acquires TRACE Analytics, Enabling On-line Bioanalytics
908 Devices to Participate in the Canaccord Genuity 42nd Annual Growth Conference
908 Devices to Report Second Quarter 2022 Financial Results on August 9, 2022
908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS
908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference
908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook
908 Devices Advances MX908 Handheld Device Capabilities
908 Devices Partners with Key Biomanufacturing Innovation Center
908 Devices and CPI Team on Cell Culture Media Optimization for Improved Process Control in Bioprocessing Applications
908 Devices to Report First Quarter Financial Results on May 10, 2022
908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook
908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors
908 Devices to Report Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer
908 Devices and U.S. Forest Service Announce Development Collaboration
908 Devices Teams with World-Renowned Guardian Centers of Georgia for First Responder Training
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Announces Pricing of Public Offering
908 Devices Announces Launch of Public Offering
908 Devices Reports Third Quarter 2021 Financial Results
908 Devices Launches Oligos Kit for its ZipChip CE-MS Device
908 Devices to Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows
908 Devices to Report Third Quarter Financial Results on November 4, 2021
908 Devices Reports Second Quarter 2021 Financial Results and Raises 2021 Revenue Outlook
908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel
908 Devices Expands Strategic Distribution Network in APAC, Europe, and the Americas
908 Devices and Transcenta’s Joint Innovation Partnership Accelerates Biopharma Development
908 Devices to Report Second Quarter Financial Results on August 4, 2021
908 Devices Announces New Data Integrations with Key Industry Partners to Accelerate BioProcess Data Insights
908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer, Labcorp Diagnostics, to its Board of Directors
908 Devices to Participate in the William Blair 41st Annual Growth Stock Conference
908 Devices Reports First Quarter 2021 Financial Results and Reiterates 2021 Revenue Outlook
908 Devices Launches New Aerosol Module for Handheld MX908
908 Devices Increases Focus on Biotherapeutics with Expansion of Scientific Advisory Board
908 Devices and Bio-Techne Announce Joint Collaboration
908 Devices to Report First Quarter Financial Results on May 13, 2021 and Host 2021 Annual Meeting of Stockholders on June 17, 2021
908 Devices Appoints Michele Fournier as Chief People Officer
908 Devices Provides Handheld Mass Spec for Trace Detection to U.S. Border Patrol
908 Devices Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Revenue Outlook
908 Devices Awarded Multi-Year $25M Purchase Order to Enable the U.S. Army
908 Devices Appoints Jeff George and Fenel Eloi to its Board of Directors
908 Devices to Report Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Strengthens Commercial Team with Addition of New Vice President
Ohio Attorney General Agencies Deploy 908 Devices Handheld Mass Spec Device to Aid Law Enforcement Cases Involving Illicit Drugs
908 Devices Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
908 Devices Announces Pricing of Initial Public Offering
908 Devices Names Kevin Hrusovsky, 30-year Biotechnology Veteran and Founder of Powering Precision Health, as Chairman of its Board of Directors
908 Devices Announces New Additions to Its Executive Team
SCIEX and 908 Devices Launch Solutions for the Characterization of Biotherapeutics
MX908 Selected for Central European CBRN-E Training Center’s First Response Training Program
Southern Scientific and 908 Devices Enter UK Distribution Partnership for MX908
Cell Culture Dish Presents Cool Tools – The Rebel Analyzer Enables Real-Time Comprehensive Media Analysis in a Benchtop Package
Teaming Up For Solutions
908 Devices and Transcenta Expand Joint Innovation Partnership
Our response to COVID-19
908 Devices’ Rebel named one of 2019’s top transformational laboratory technologies
Dr. Christopher D. Brown of 908 Device’s Receives Coblentz Society’s Williams-Wright Award
Police One: How do you fight America’s deadliest drug?
The Analytical Scientist ranks 908 Devices’ Rebel as one of the top transformational technologies in 2019
FEMA’s Center for Domestic Preparedness (CDP) Integrates MX908 into Hazardous Materials Training Course
US Marine Corps relies on MX908 for multi-mission trace detection
Police Chief Magazine: Narcotics Detection Science Keeps Pace with the Street
WBUR Boston: Boston Is Using A Chemical Warfare Device To Help Fight Fentanyl
BioPharma Reporter: 908 Devices launches a Rebel-lion in media analyzing
GEN: The Rebel Accelerates Process Development Cycles and Maximizes Bioreactor Utilization
908 Devices launches the Rebel, the first at-line spent cell media analyzer for bioprocess labs
908 Devices poised to modernize upstream bioprocess analytics with a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
908 Devices Addresses Emerging Novichok Nerve Agent Threat, Expands Capabilities for MX908 Chemical Detection Device
908 Devices broadens the ZipChip platform, brings new capability to biotherapeutics researchers
Miniaturization: A ‘Renaissance’ for Mass Spectrometers
908 Devices Secures $17.5 Million in Growth Funding
MX908 Used to Identify Substance That Hospitalized Police Officers in MA
908 Devices’ High-Pressure Mass Spectrometry (HPMS) Technology to Power Next-Generation Advanced Chemical Threat Detector for U.S. Department of Defense
Massachusetts Governor Charlie Baker tours new 908 Devices Boston Headquarters
908 Devices’ MX908 out-designs designer drugs, unlocks detection capabilities for more than 2000 fentanyl variants
908 Devices and Hangzhou Just Biotherapeutics Announce Joint Innovation Partnership
908 Devices Expands ZipChip Application in Drug Discovery; Industry-leading Mass Spectrometers Added to Compatibility Roster
908 Devices Bolsters Life Science Leadership, Welcomes Nicolas Barthelemy to Board of Directors
908 Devices Launches Drug Hunter Mission Mode to Combat Fentanyl and High Priority Drugs
908 Devices Optimizes High-Quality Mass Spec Analysis Through Partnership Agreement with Thermo Fisher Scientific
908 Devices Strengthens Life Science Leadership Team and Unveils Transformational Advancements to ZipChip
Thermo Fisher Scientific and 908 Devices to Demonstrate Innovative Separation Technology with Industry-Leading Orbitrap Mass Spectrometers at ASMS 2016
908 Devices Expands First Responder Toolkits in the Nation’s Capital with the Addition of Handheld Mass Spectrometers
908 Devices Equips State of Massachusetts’ Hazardous Materials Emergency Response Division with Handheld Mass Spectrometry for Downrange Chemical Detection
908 Devices Announces International Expansion
Subscribe to Our Communications
Signup to receive new product updates, technical tips and more.